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Purpose: CGX is a modiﬁcation of a traditional Korean
herbal medicine, which is under clinical trial phase III for
hepatoﬁbrosis therapeutic effect. The objective is to present
the status for CGX development regarding its clinical back-
grounds, pharmacological studies in animal models, and
current process of randomized clinical trial.
Methods: CGX has been used for patients suffering various
liver diseases, including chronic viral hepatitis and alcoholic
liver disorders. The safety of CGX was evaluated in animal-
based repeated toxicological studies using rats and beagle
dogs. The pharmacological actions against hepatic ﬁbrosis
were evidenced in various chronic liver injury animal models
using chemicals (CCl4, DMN, or TAA), chronic alcohol con-
sumption, choline-deﬁcient (MCD) diet, and bile duct ligation
(BDL) respectively. It is now under a ramdomized controlled
multicenter trial.phase III for hepatoﬁbrosis.
Results: The total number of participants is 174 in 2 Hos-
pitals, who are suffering from chronic HBV, HCV or Alcoholic
liver disease. The inclusion criteria is patientswith LSM5.5 kPa
to 16kPa, aged between 18∼75 year. The exclusion criteria
is the conditions of too severe status as follows; ascites,
esophageal varix, TB > 3mg/dl, AST, ALT > ULN > 5 folds, INR
> 2.0 or platelet < 80,000/mm3 and BMI > 30. The drug treat-
ment period is 6 months for 3 groups (placebo, 1gram or 2
gram of CGX daily). The primary measurement is the changed
value of LSM (liver stiffness mesurement) during 6 months,
and the secondary measurements are the changed value of
hyaluronic acid (HA), serumTGF-1, PDGF, AST to platelet ratio
index (APRI) and QOL (SF-36) respectively.
Conclusion: It is expected that multi-sites clinical trial evi-
dences the ﬁbro-therapeutic effects of CGX in patients with
chronic viral or alcoholic liver diseases.
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Purpose: Modiﬁed Yu ping feng san Formula is widely
applied for allergic rhinitis in children in China. Many clin-
ical trials are reported. This study assessed the efﬁcacy and
safety of modiﬁed Yu ping feng san Formula for the treatment
of allergic rhinitis in children.
Methods: PubMed, Cochrane CENTRAL, and four Chinese
databases were searched through July 2014. We included ran-
domised controlled trials (RCTs) that tested modiﬁed Yu ping
feng san Formula for allergic rhinitis in children, compared
with no intervention, placebo, pharmaceutical medication.
Authors extracted data and assessed the quality indepen-
dently. We applied RevMan 5.2.0 software to analyse data of
included randomised trials.
Results: A total of 13 RCTs involving 1177 participants
were identiﬁed. The methodological quality of the included
trials was generally poor. Meta-analyses of two trials demon-
strated that modiﬁed Yu ping feng san Formula were more
effective than pharmaceutical medication alone in improv-
ing nasal symptoms and clinical signs (RR 0.67, 95% CI 0.46
to 0.97). Meta-analyses of two trials demonstrated that modi-
ﬁedYuping feng san Formula plus pharmaceuticalmedication
were more effective than pharmaceutical medication alone in
improving nasal symptoms and clinical signs (RR 0.78, 95% CI
0.62 to 0.97). Meta-analyses of three trials demonstrated that
modiﬁed Yu ping feng san Formula plus pharmaceutical med-
ication were more effective than pharmaceutical medication
alone in controlling recurrence of allergic rhinitis in one year
after drug withdrawal (RR 0.62, 95% CI 0.52 to 0.75). No serious
adverse events were reported.
Conclusion: The modiﬁed Yu ping feng san Formula
appears to have additional beneﬁt based on pharmaceutical
medication treatment in improving nasal symptoms and clin-
ical signs and recurrence of allergic rhinitis. However, due to
high risk of bias of the trials, we could not draw conﬁrma-
tive conclusions on its beneﬁt. Future clinical trials should be
well-designed and avoid the issues that are identiﬁed in this
study.
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